AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04439071 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets
Study NCT00475618 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: topical fluoride varnish application.
Description: Vanish application every 6 months in all accesible tooth surfaces
Study NCT00475618 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: professional cleaning
Description: Daily use fluoride toothpaste 500 ppm.
Study NCT00475618 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No fluoride toothpaste
Description: Daily use no fluoride toothpaste.
Study NCT00194766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide 75 mg/m2 daily for 6 weeks followed by a two week rest period for a total cycle length of 8 weeks. Treatment is repeated until disease progression, excessive toxicity or other reason to suspend protocol treatment.
Study NCT03829709 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: The first training session each week will be held at the LAERF under the direct supervision of the investigator and the other two home-based training sessions under the supervisor's distance supervision. They will receive the Threshold® IMT linear loading device, and guidelines for handling, posture and asepsis. The initial training load for each participant will be adjusted to 25% of PiMáx. Participants will be trained and instructed to do the exercise program on their own at home. Once a week, during the return to the laboratory the researcher will determine the new values for load (1st week 25%, 2nd week 35%, 3rd week 40%, 4th week 45%, 5th week 50%).
Study NCT02734823 — intervention group
Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Undergo collection of serum
Study NCT02734823 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02734823 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02734823 — intervention group
Intervention type: PROCEDURE
Intervention: Ultrasonography
Description: Undergo transvaginal pelvic ultrasonography
Study NCT02783716 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous adipose tissue collection
Description: During standard of care device implantation procedure, a small piece of fat tissue will be removed from the device pocket inside the chest
Study NCT02783716 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral arterial tonometry (PAT)
Description: Non-invasive testing for blood vessel function. Specially designed finger probes placed on the middle finger of each hand. Pulsatile volume changes of the distal digit inducing pressure alterations in the finger cuff will be sensed by pressure transducers and recorded. Endothelial function will be measured via a reactive hyperemia (RH)-PAT index (RHI)
Study NCT04679779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: designed occupational therapy program
Description: Exercises facilitating hand skill patterns will include basic reach, grasp, carry and release and the more complex skills of in-hand manipulation and bilateral hand use.
Study NCT04679779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wii virtual reality games
Description: 1. Bowling~2. Frisbee~3. Basketball~4. Boxing
Study NCT00227487 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Stool collection
Description: Stool sample will be obtained by parent at home to prevent sample dilution during the cleanout
Study NCT00227487 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Administration of carbohydrate solution during clinically indicated endoscopy
Description: * A carbohydrate solution (lactulose + rhamnose dissolved in tap water) will be administered during the procedure (upper endoscopy) through a catheter directly into the duodenum to allow for intestinal permeability analysis.~* Clinically indicated pinch biopsies will then be obtained.~* The endoscopy procedures will take at least 1 - 1 ½ hours.~* Children will then typically recover in the endoscopy suite for 2 - 2½ hours or less, if the child is medically cleared to leave the endoscopy suite sooner.~* Urine for intestinal permeability analysis will be collected during 5 hours after carbohydrate solution administration. If the child has not voided, an additional 60 minutes will be allowed for the child to void. If the child is not continent for urine, a bag will be applied to catch the specimen.
Study NCT00227487 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: Parents/legal guardians of subjects will be asked to complete five (5) questionnaires: the Gastrointestinal Symptoms Inventory; a Developmental Screening for Autism - based on the child's age, either the Checklist for Autism in Toddlers (CHAT), Modified Checklist for Autism in Toddlers (M-CHAT), or the Social Communication Questionnaire (SCQ); the Behavior and Sensory Interest Questionnaire (BSI), the Behavior Problems Inventory (BPI), and the Aberrant Behavior Checklist (ABC). It should take parents/guardians no longer than eighty-five (85) minutes to complete all 5 surveys. Results from these questionnaires will be correlated with documented gastrointestinal and/or neurological diagnostic information from subject medical records and with research study test results.
Study NCT00690625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MyoRx Cream (6% Omega 3 Fatty Acid)
Description: 1/2 teaspoon 3 times per day for 30 days.
Study NCT00690625 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream, no Omega 3 fatty acid
Description: Placebo cream, no Omega 3 fatty acid
Study NCT03288870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-100
Description: monoclonal antibody to PD-1 receptor
Study NCT03288870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Chemotherapy drug (taxane)
Study NCT01426516 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genecept Assay
Description: Genetic test which analyzes five pharmacodynamic and two pharmacokinetic genes important in psychiatric disorders
Study NCT01157013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positron emission tomography with fludeoxyglucose F 18
Description: Patients receive fludeoxyglucose F 18 (\^18FDG) IV. Beginning 1 hour later, patients undergo whole-body positron emission tomography (PET) scanning. Patients also undergo conventional radiographic staging of their disease.
Study NCT01727583 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: meal intake
Description: Intake of meals characterized by lipid composition
Study NCT01727583 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04139265 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: biologic analysis (ferritinemia, transferrin saturation coefficient)
Description: Each patient will follow a blood test in order to compare between ferritinemia and transferrin saturation coefficient in iron deficiency diagnosis
Study NCT01285466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEZ235 + paclitaxel
Study NCT01285466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120 + paclitaxel
Study NCT01285466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEZ235 + paclitaxel + trastuzumab
Study NCT01285466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120 + paclitaxel + trastuzumab
Study NCT00227188 — intervention group
Intervention type: DRUG
Intervention: Pneumococcal 7-valent conjugate vaccine Prevnar
Study NCT03167957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Encochleated Amphotericin B (CAMB)
Description: Lipid-crystal nano-particle formulation amphotericin B
Study NCT02718807 — intervention group
Intervention type: OTHER
Intervention: RP model explanation and questionnaire
Description: Rapid prototyping models of anatomy will be used to demonstrate an anatomic and medical condition and participants will grade the experience on a questionnaire.
Study NCT03938038 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Serial ultrasound assessments for GDT
Description: routine ultrasound assessments of volume status and fluid responsiveness for goal-directed therapy (GDT)-based fluid resuscitation
Study NCT03938038 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Close hemodynamic cardiac monitoring and volume responsiveness assessment on an unscheduled basis to aid physicians in resuscitation feedback
Study NCT01464125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosmidomycin
Description: Fosmidomycin sodium capsules 450 mg x 4 twelve-hourly for three days
Study NCT01464125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin capsules 250 mg x 3 twelve-hourly for three days
Study NCT02849340 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryosurgery
Description: Percutaneous ablation under CT or ultrasound guidance
Study NCT02849340 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryosurgery
Description: Percutaneous ablation under CT or ultrasound guidance
Study NCT02849340 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK immunotherapy
Description: Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
Study NCT01161901 — intervention group
Intervention type: PROCEDURE
Intervention: blood sample
Description: This study's hypothesis is that patients with ARDS criteria and lobar morphology on CT scan present loss of aeration but no inflammatory pulmonary oedema, whereas patients with non lobar morphology on CT scan present both characteristics.~The primary purpose of our protocol is to show that the patients who respond to ARDS criteria and have a lobar morphology on CT scan do not have an elevation of the biomarkers specific to the pulmonary aggression of ARDS.
Study NCT02685553 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIR
Description: Laparoscopic use of NIR
Study NCT00525889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Administered by subcutaneous injection at a dose of 4.5x10\^6 IU/day, three times weekly for 28 days starting on day 0.
Study NCT00525889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: Administered orally, initial daily dose of 2mg. At day 7, dose adjusted to achieve and maintain whole blood trough levels of 5-10 ng/ml.
Study NCT01835197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842
Description: Subjects will receive single doses of 3, 10, 30, 100, 200, 400, or 800 mg of PF-04695842 (solution or suspension) in a dose escalation format.
Study NCT01835197 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive single doses of PF-04695842 matching placebo (solution or suspension) in a dose escalation format.
Study NCT01835197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842
Description: Subjects will receive doses of 30, 100 or 200 mg (solution or suspension) once daily for 10 days.
Study NCT01835197 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive PF-04965842 matching placebo (solution or suspension) once daily for 10 days.
Study NCT01835197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842
Description: Subjects will receive doses of 100 or 200 mg (suspension or solution) twice daily for 10 days.
Study NCT01835197 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive PF-04965842 matching placebo doses (suspension or solution) twice daily for 10 days.
Study NCT01835197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842
Description: Subjects will receive 200 mg dose (suspension or solution) twice daily for 10 days.
Study NCT01835197 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive PF-04965842 matching placebo dose (suspension or solution) twice daily for 10 days.
Study NCT01835197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842
Description: Subjects will receive 400 mg dose (suspension or solution) once daily for 10 days.
Study NCT01835197 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive PF-04965842 matching placebo dose (suspension or solution) once daily for 10 days.
Study NCT00807963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: recombinant human hyaluronidase PH20 injection
Study NCT00807963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: subcutaneous injection
Study NCT01479114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rh-GCSF
Description: 10 ug/kg/day intravenously for 3 days
Study NCT02637115 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Consumption of one dose-sachet per day. This dose-sachet contains a placebo (PBS/Glycerol)
Study NCT02637115 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Live Akk 9
Description: Consumption of one dose-sachet per day. This dose-sachet contains Live Akkermansia muciniphila (one billion per dose-sachet)
Study NCT02637115 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Live Akk 10
Description: Consumption of one dose-sachet per day. This dose-sachet contains Live Akkermansia muciniphila (ten billion per dose-sachet)
Study NCT02637115 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Killed Akk
Description: Consumption of one dose-sachet per day. This dose-sachet contains heat-killed Akkermansia muciniphila
Study NCT03509896 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study NCT01418651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savella
Description: milnacipran 25 to 200 mg daily, divided into two doses (morning and evening)
Study NCT00129623 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po monthly for 1 year
Study NCT00129623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate [Bonviva/Boniva]
Description: 150mg po monthly for 1 year
Study NCT00450658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HZT-501
Description: HZT-501: Ibuprofen 800mg/famotidine 26.6mg orally 3 times daily for 24 weeks
Study NCT00450658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen 800mg orally 3 times daily for 24 weeks
Study NCT04592913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Human monoclonal antibody
Study NCT04592913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLOT chemotherapy
Description: A combination treatment made up of flurouroacil + leucovorin + oxaliplatin + docetaxel
Study NCT04592913 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FLOT chemotherapy
Description: A combination treatment made up of flurouroacil + leucovorin + oxaliplatin + docetaxel
Study NCT03220477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered at 200mg IV on day 1 of each 21 day cycle.
Study NCT03220477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Description: Guadecitabine will be administered subcutaneously given daily on days 1-5 of each cycle with escalating doses by cohort.
Study NCT03220477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mocetinostat
Description: Mocetinostat will be administered orally with escalating doses on days 8, 10, 13, 15, 17 and 20 of each cycle with escalating doses by cohort.
Study NCT01842386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Subjects will receive intravenous (IV) infusions of rituximab 1 gram on days 1 and 15, and subsequently if indicated up to once a month for 5 months (+/-5 days for each visit) starting approximately on day 42. Subjects whose infections respond positively to the treatment but then relapse may be offered additional treatment.
Study NCT03589690 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha lipoic acid
Description: 22 Patients will consume 600 mg Alpha lipoic acid for 12 weeks .
Study NCT03589690 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be supplemented with 600 mg/day placebo (Starch).
Study NCT00536809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: onced daily Days 1-21
Study NCT00536809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Day one of each cycle
Study NCT00536809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: given BID days 1-14
Study NCT00460174 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 10 mg/kg every 2 weeks as an intravenous infusion after gemcitabine and before radiation
Study NCT00460174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1000 mg/m2, 30 minute intravenous infusion, cycle 1 (weeks 1, 2), cycle 2 (weeks 4, 5, 6) and cycle 3 (weeks 8 and 9). During cycle 2, gemcitabine will be delivered prior to radiation therapy
Study NCT00460174 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: If resectable, patients will undergo surgery no less than 6 weeks following last dose of bevacizumab. Unresectable patients will not undergo surgery.
Study NCT00460174 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 2.4 Gy fractions, 5 fractions/week during cycle 2 only (weeks 4, 5, 6). Total dose 36 Gy.
Study NCT02724124 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static Stretching
Description: 3 sets of 30-second self static hamstring stretch (IT), quadriceps (QD) and sural triceps (TS) of both lower limbs, with an interval of 30 seconds of rest between sets
Study NCT02724124 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: warm up
Description: Warm-up for 10 minutes at 70-80% of maximum heart rate.
Study NCT02724124 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: static stretching + warm up
Description: 3 sets of 30-second self static hamstring stretch (IT), quadriceps (QD) and sural triceps (TS) of both lower limbs, with an interval of 30 seconds of rest between sets + Warm-up for 10 minutes at 70-80% of maximum heart rate.
Study NCT02724124 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: warm up+static stretching
Description: Warm-up for 10 minutes at 70-80% of maximum heart rate + 3 sets of 30-second self static hamstring stretch (IT), quadriceps (QD) and sural triceps (TS) of both lower limbs, with an interval of 30 seconds of rest between sets
Study NCT02724124 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: No intervention
Study NCT01353625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-115
Description: Part A (actively recruiting): Dose level starts with 0.5mg daily by mouth in cycles of 28 days. Level increases for different patient cohorts in 100% or 50% increments until optimal dose schedule is established for further study. Treatment continues for as long as patient benefits (i.e., until disease progression or unacceptable toxicity).~Part B: Optimal dose schedule is administered in 28-day cycles until disease progression.
Study NCT01245634 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: iv infusion every 4 weeks, 32 weeks
Study NCT01245634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4905417
Description: 20 mg/kg iv infusion every 4 weeks, 32 weeks
Study NCT04029350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Combined With Osimertinib
Description: Anlotinib：12mg/capsule, take once when limosis in the morning. If patients suffer from AEs, they can get declined dosage (10mg or 8mg).~Osimertinib：80 mg/tablet， per os (p.o.) daily. It should be continued until disease progression or intolerable toxicity or patients withdraw of consent.
Study NCT03954574 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: assessment of pulmonary hemodynamics during exercise by right heart catheterization
Description: all patients undergo right heart catheterization during exercise due to clinical reasons. Results of this and other Routine clinical tests will be included in the registry
Study NCT03715023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PC786
Description: PC786 suspension for inhalation
Study NCT03715023 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution for inhalation
Study NCT03715023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC
Description: Standard treatment for RSV infection at study site
Study NCT03715023 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SOC
Description: Standard treatment for RSV infection at study site
Study NCT00668278 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insertion of I-gel airway
Description: Insertion of I-gel airway under anaesthesia; Fentanyl 1-2mcg/kg; Propofol 1-3mg/kg; Atracurium 0.5mg/kg